Programmed cell death ligand 1 (PD-L1) forms part of the PD-1/PD-L1 pathway exploited by neoplasms to evade immune surveillance, and its inhibition has been shown to be clinically efficacious against a number of cancers (26, 32, 33). This evidence concerns the gene CD274 and cancer.